Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
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
UgETbCkKD6nF0EQB